Development of Therapeutics for Biodefense
$14,315,157N01FY2011AINIH
Enanta Pharmaceuticals, Inc., Watertown MA
Investigators
Abstract
This contract supports the advanced development of promising biodefense therapeutic candidates/products with broad spectrum activity. The research and development activities supported will allow candidate therapeutic countermeasures to progress through the product development pipeline, and includes preclinical/non-clinical and clinical IND development activities.
View original record on NIH RePORTER →